STOCK TITAN

BioAtla (BCAB) SEC Filings

BCAB OTC

BioAtla, Inc. filings document the regulatory record for a clinical-stage biotechnology company developing CAB antibody therapeutics for solid tumors. Recent Form 8-K disclosures cover financial results, investor presentation materials, cost-reduction actions, executive retention compensation, financing arrangements, license-related updates and risk-linked operating disclosures.

The filings also record capital-structure and governance matters, including shareholder votes on stock issuance and reverse split authority, Series A Junior Preferred Stock issuance and elimination, Nasdaq continued-listing proceedings, and a Delaware certificate of merger connected to a common-stock reclassification.

Rhea-AI Summary

BioAtla, Inc. (BCAB) reported net losses of $7.897 million for the three months and $13.789 million for the nine months ended September 30, 2026, versus $15.778 million and $49.823 million in 2025. Nine-month collaboration revenue was $6.750 million from Context and EXUMA license amendments. Cash was $576,000 at September 30, and results included a $4.858 million operating lease right-of-use asset impairment. Management concluded substantial doubt exists about BioAtla’s ability to continue as a going concern for at least one year from issuance.

BioAtla paused enrollment in its BA3182 Phase 1 study while continuing treatment and patient follow-up. At September 30, it was not in compliance with certain lease financial covenants and was negotiating a resolution with its landlord. Its post-quarter 2026 SEPA gives it the right, but not the obligation, to sell up to $40.0 million of shares over 36 months; a registration effective October 29 permits Yorkville’s resale of up to 8,182,110 shares. On November 10, BioAtla issued related party Inversagen AI LLC a nonconvertible $400,000 note at 10% annual interest; Chairman and Chief Executive Officer Dr. Jay M. Short and his spouse are managers of Inversagen AI.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.56%
Tags
quarterly report
-
EFFECT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
other
-
Rhea-AI Summary

BioAtla, Inc. registered up to 8,182,110 common shares for resale by YA II PN, Ltd.: up to 8,000,000 Advance Shares it may elect to issue and sell under the Standby Equity Purchase Agreement, plus 182,110 shares issuable upon exercise of Commitment Fee Warrants. BioAtla receives no proceeds from resales, but may receive up to $40,000,000 in gross proceeds from elected Advance Share sales during the 36 months after October 15, 2026.

Yorkville pays 97% of the lowest daily VWAP during the three trading days beginning with an advance notice, excluding Excluded Days; purchases are subject to a 4.99% beneficial-ownership cap. BioAtla had 1,668,261 shares outstanding as of October 16, 2026; all registered shares issued then would equal approximately 490.5% of that count.

BioAtla is exploring asset sales, licensing, partnerships and other strategic transactions, with no assurance of an agreement; restructuring included a workforce reduction of approximately 70%. Further enrollment in Phase 1 BA3182 was paused, while treatment and follow-up continued. Cash and cash equivalents were approximately $1.5 million as of June 30, 2026; BioAtla said these resources were insufficient to fund ongoing operations for at least 12 months from issuance of the financial statements, raising substantial doubt about its ability to continue as a going concern.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
prospectus
RW
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
other
-
Rhea-AI Summary

BioAtla, Inc. (BCAB) registered for resale up to 8,182,110 shares of common stock by YA II PN, Ltd. (Yorkville), comprising up to 8,000,000 Advance Shares BioAtla may elect to issue and sell under its Standby Equity Purchase Agreement (SEPA) and 182,110 shares issuable upon exercise of commitment fee warrants. BioAtla receives no proceeds from Yorkville’s resales, but may receive up to $40,000,000 in aggregate gross proceeds from Advance Shares it elects to sell during the SEPA’s 36-month term, subject to the agreement’s conditions.

As of June 30, 2026, BioAtla reported approximately $1.5 million in cash and cash equivalents, which it said was insufficient to fund operations for at least 12 months from issuance of its interim financial statements, raising substantial doubt about its ability to continue as a going concern. BioAtla paused further enrollment in its Phase 1 BA3182 study while continuing treatment and patient follow-up as it re-evaluates clinical timelines amid its strategic-options process.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
registration
-
Rhea-AI Summary

BioAtla, Inc. entered into a new standby equity purchase agreement with YA II PN, Ltd. (Yorkville), giving BioAtla the right, but not the obligation, to sell up to $40.0 million of common stock during the 36 months following October 15, 2026. Yorkville's purchase price is 97% of the lowest daily VWAP during the three consecutive trading days commencing with delivery of an advance notice, excluding a day when VWAP is below BioAtla's stated minimum acceptable price or no VWAP is available. BioAtla may not deliver an advance notice until a resale registration statement is effective, and Yorkville and its affiliates may not purchase shares that would result in beneficial ownership above 4.99% of the then-outstanding voting power or share count of BioAtla common stock.

BioAtla agreed to a $500,000 commitment fee, payable in two equal installments in cash or warrants at its election; on October 16, 2026, it issued warrants exercisable for 182,110 shares for the first installment. BioAtla also terminated its prior SEPA, which allowed sales of up to $15.0 million. Before termination, BioAtla had sold 48,092 shares under that agreement for approximately $0.4 million in gross proceeds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
current report
Rhea-AI Summary

BioAtla, Inc. (BCAB) disclosed that Dr. Eric Sievers resigned as chief medical officer on September 25, 2026, and will consult through June 30, 2027. For requested consulting services through December 31, 2026, he is eligible for a one-time $159,000 payment contingent on the company achieving certain capital-raising milestones by that date. Services from January 1 through June 30, 2027, are paid hourly at a rate proportional to his base salary at separation.

On September 24, 2026, the board reinstated selected retention-bonus terms for CEO Jay M. Short and CFO Christian Vasquez, subject to milestones by December 31, 2026. Short's $440,892 target requires 100% achievement; Vasquez's $148,888 target pays proportionally from 80% to 120% for results within 20% below or above the milestone, with no payout if it is missed by more than 20%. Both must be employed and in good standing at payout. Separate performance bonuses of $220,000 for Short and $75,000 for Vasquez depend on milestones by March 31, 2027; payment is due by April 30, 2027, subject to the same employment condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
current report
-
Rhea-AI Summary

BioAtla, Inc. (BCAB) reported that Chief Medical Officer Eric Sievers had 134 shares of common stock withheld on August 31, 2026 to satisfy income tax and withholding obligations related to the vesting and net settlement of previously reported restricted stock units. This was not an open-market sale, and he beneficially holds 11,346 shares directly after the transaction. No transactions were made under a Rule 10b5-1 trading plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.88%
Tags
insider
-
Rhea-AI Summary

BioAtla, Inc. (BCAB) reported that Chief Executive Officer and director Jay M. Short, Ph.D., had 259 shares of common stock withheld on August 31, 2026 to pay income tax and related withholding obligations arising from the vesting and net settlement of previously reported restricted stock units. The company states this is not a sale of shares by Dr. Short. After this tax-withholding disposition, he holds 52,035 common shares directly and additional indirect holdings through his spouse, several 2020 irrevocable gift trusts, Capia IP, LLC, and Himalaya Parent LLC, with beneficial ownership of the latter disclaimed except to the extent of his or his spouse’s pecuniary interest. No Rule 10b5-1 trading plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.88%
Tags
insider
Rhea-AI Summary

BioAtla, Inc. (BCAB) reported that Chief Financial Officer Christian Vasquez had 71 shares of common stock withheld on August 31, 2026 to pay income tax obligations related to the vesting and net settlement of previously reported restricted stock units. This was not an open-market sale; the shares were withheld by the company for tax and remittance purposes. Following this tax-withholding transaction, Vasquez directly holds 10,476 shares of BioAtla common stock, including shares purchased under the company’s ESPP.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.88%
Tags
insider

FAQ

How many BioAtla (BCAB) SEC filings are available on StockTitan?

StockTitan tracks 62 SEC filings for BioAtla (BCAB), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for BioAtla (BCAB)?

The most recent SEC filing for BioAtla (BCAB) was filed on November 16, 2026.